Yunnan Biovalley

Yunnan Biovalley Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, production, and sale of modern Traditional Chinese Medicine (TCM) for cardiovascular and cerebrovascular diseases. The company is a leading player in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource native to Yunnan province. Its flagship products include Dengzhan Shengmai Capsules and Dengzhanhua Injection, which are widely used in the treatment of ischemic stroke and coronary heart disease. Biovalley operates a full industry chain, from standardized cultivation of medicinal herbs to high-tech pharmaceutical manufacturing. The company is listed on the Beijing Stock Exchange and focuses on evidence-based medicine to validate the efficacy of its botanical therapies.